EU approves Etcamah and advances Enhertu combination for biomarker-defined breast cancers
- nuaxia
- Jul 31
- 2 min read
The two regulatory decisions could expand first-line treatment options for patients with ESR1-mutant ER-positive disease and HER2-positive metastatic breast cancer, although Enhertu still requires European Commission approval.
The European Commission has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for adults with ESR1-mutant, ER-positive, HER2-negative locally advanced or metastatic breast cancer whose disease has not progressed during first-line endocrine therapy, while the EMA’s CHMP has recommended Enhertu (trastuzumab deruxtecan) with pertuzumab for first-line unresectable or metastatic HER2-positive breast cancer.
Etcamah introduces a biomarker-triggered treatment switch before clinical progression, whereas the Enhertu combination could provide a new first-line option if the Commission endorses the CHMP opinion.
Field | Content |
Alert Type | Drug Approval |
Drug Name | Etcamah (camizestrant); Enhertu (trastuzumab deruxtecan) in combination with pertuzumab |
Indication | Etcamah with palbociclib, ribociclib or abemaciclib: adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of an ESR1 mutation and without disease progression during first-line endocrine therapy with a CDK4/6 inhibitor. Enhertu with pertuzumab: proposed first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer. (ema.europa.eu) |
Therapy Area(s) | Oncology; Breast cancer |
Geography | European Union — European Commission and EMA Committee for Medicinal Products for Human Use |
What Happened | The European Commission granted marketing authorisation for Etcamah on 20 July 2026, following the CHMP’s positive opinion in May. The approval permits clinicians to replace the aromatase-inhibitor component of first-line therapy with camizestrant when an ESR1 mutation is detected, while continuing the existing CDK4/6 inhibitor. Separately, on 23 July 2026, the CHMP recommended extending Enhertu’s authorisation to include its use with pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer; this is a recommendation rather than a final EU approval. (ema.europa.eu) |
Why It Matters | Etcamah provides a treatment strategy based on detecting emerging endocrine resistance before radiological disease progression, offering eligible patients an alternative endocrine backbone while retaining their CDK4/6 inhibitor. The Enhertu opinion could move the antibody–drug conjugate into the first-line setting, where taxane, trastuzumab and pertuzumab has remained a standard approach for more than a decade, but clinical use in this setting depends on a final Commission decision. (ema.europa.eu) |
Supporting Context | In SERENA-6, median progression-free survival was approximately 17 months with Etcamah plus a CDK4/6 inhibitor versus around nine months when patients continued letrozole or anastrozole with the inhibitor. In DESTINY-Breast09, Enhertu plus pertuzumab produced median progression-free survival of 40.7 months versus 26.9 months with taxane, trastuzumab and pertuzumab, with no new safety concerns identified by the companies. (ema.europa.eu) |
Key Takeaway | The Etcamah approval and Enhertu recommendation advance two distinct biomarker-led first-line strategies for advanced breast cancer in Europe. |
What to Watch | The European Commission’s final decision on the Enhertu–pertuzumab indication and the implementation of ESR1 mutation monitoring to identify patients eligible for an Etcamah treatment switch. |
Primary Source | |
Relevant Date | 23 July 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments